Feedback II – The GVAX Cancer Vaccine Trial at the Dana Farber

The GVAX cancer vaccine clinical trial, which has been opened in January 2006 is no more recruiting new patients. When it was open it recruited in addition to Alveolar Soft Part Sarcoma also Clear Cell Sarcoma, Renal Cell Carcinoma and Melanoma patients. In June 2007 I shared with you an e-mail from a parent whose […]

A Press Release – ARQ197

ArQule Achieves Clinical Milestone in MiT Trial with ARQ 197 Thursday October 2, 8:01 am ET Confirmed tumor response in clear cell sarcoma leads to expanded trial WOBURN, Mass.–(BUSINESS WIRE)–ArQule, Inc. (NASDAQ: ARQL – News) today announced the expansion of its Phase 2 trial with ARQ 197, a proprietary, orally administered small molecule inhibitor of […]

Research sponsored by iCureASPS published: Is ASPS a target for Halofuginone therapy?

Cure Alveolar Soft Part Sarcoma International is very proud to announce the publication of a study that was supported by donations through our organization. The new study appears in the scientific journal ”Neoplasia”. It focuses on genes which are expressed in alveolar soft part sarcoma and in the normal cells surrounding the tumor. Those cells […]

Team ASPS dedicated a 50-mile bike ride to the Team Sarcoma Initiative

Team iCureASPS dedicated a 50 mile bike ride to the 2008 Team Sarcoma Initiative. The ride was on the route between Wellesley and Wrentham, MA. It was the last training session for our riders who are preparing for the PMC bike ride that will take place during this coming weekend. The international sarcoma awareness week […]

Update: ARQ 197 – New Clinical Trial for Patients with Alveolar Soft Part Sarcoma

Previously, we reported that Alveolar Soft Part Sarcoma is a candidate for therapy by drugs that inhibit the MET receptor tyrosine kinase. Then, we reported the opening of a clinical trial of such an inhibitor, ARQ 197, in California. This clinical trial is now open in many more locations in the USA, and may soon be available in […]